Pharma Business - November 29, 2016
Novo Nordisk receives US FDA approval
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy 100/3.6. Xultophy 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or […]
Uncategorized - November 14, 2016
Novo expands its Changing Diabetes in Children programme
On the World Diabetes Day, Novo Nordisk announced a four-year extension of its Changing Diabetes in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more […]
Careers article - October 17, 2016
Novo’s retiring CEO named the world’s best CEO again
The Harvard Business Review (HBR) puts out a ranking of the “best-performing” CEOs in the world every year, and the big pharma chief Lars Rebien Sorensen has topped it for the second year running. Sørensen and his fellow CEOs were judged on a variety of financial, environmental, social, and governance metrics. Martin Sorrell of British PR […]
Uncategorized - October 3, 2016
Novo Nordisk plans to cut 1000 jobs
Novo Nordisk has announced its intention to reduce its workforce by approximately 1,000 employees of the 42,300 positions in the company’s global organisation. This is one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market. The reductions are expected to affect […]
In a new job - September 5, 2016
Novo Nordisk CEO retires
Lars Rebien Sørensen, president and chief executive officer at Novo Nordisk, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. Commenting on the retirement of Lars Rebien Sørensen, Göran Ando, chairman of the Board of […]
Pharma Business - July 1, 2016
Marketing approval for Novo Nordisk
Novo Nordisk has announced the European Medicines Agency marketing approval of the mylife YpsoPump insulin pump for use with prefilled pump cartridge NovoRapid PumpCart. The approval is a key milestone for the collaboration between Novo Nordisk and Ypsomed and their goal to deliver innovative care solutions that improve the lives of people with diabetes. With its […]
